Quotes 5-day view Delayed Nyse
01/15/2021
01/19/2021
01/20/2021
01/21/2021
01/22/2021
Date
115.5(c)
119.83(c)
119.67(c)
118.28(c)
116.82(c)
Last
808 423
1 025 705
861 233
709 626
914 363
Volume
+0.23% +3.75% -0.13% -1.16% -1.23% Change
Sales 2021
3 730 M - -
Net income 2021
372 M - -
Net Debt 2021
1 874 M - -
P/E ratio 2021
57,0x
Yield 2021
-
Sales 2022
4 070 M - -
Net income 2022
416 M - -
Net Debt 2022
1 716 M - -
P/E ratio 2022
51,1x
Yield 2022
-
Capitalization
19 240 M 19 240 M -
EV / Sales 2021
5,66x
EV / Sales 2022
5,15x
Nbr of Employees
13 900
Free-Float
99,4%
Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels. The Drug Delivery Solutions...
Notations Surperformance© of Catalent, Inc.
Trading Rating : Investor Rating :
All news about CATALENT, INC.
News in other languages on CATALENT, INC.
Analyst Recommendations on CATALENT, INC.
CATALENT, INC. - 2020
The trend should continue
BUY
Moderna eyes third quarter for first doses of potential COVID-19 vaccine with Catalent deal
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends CATALENT, INC.
Short Term Mid-Term Long Term Trends Bullish Bullish Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
BUY
Number of Analysts
12
Average target price
117,64 $
Last Close Price
116,82 $
Spread / Highest target
11,3%
Spread / Average Target
0,70%
Spread / Lowest Target
-14,4%
Please enable JavaScript in your browser's settings to use dynamic charts.
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
